SCHEMBL6095881

SCHEMBL6095881

O=S(=O)(Nc1ncccn1)N1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 8/20 0.50
ALDH1A1 P00352 4/20 0.49
MAPK1 P28482 2/20 0.49
LMNA P02545 2/20 0.49
HTT P42858 1/20 0.49
KMT2A Q03164 3/20 0.49
GLA P06280 1/20 0.49
HPGD P15428 3/20 0.45
KDM4E B2RXH2 3/20 0.45
HSD17B10 Q99714 2/20 0.45
L3MBTL1 Q9Y468 3/20 0.44
MEN1 O00255 2/20 0.44
USP2 O75604 1/20 0.44
POLB P06746 1/20 0.41
APEX1 P27695 1/20 0.41
RECQL P46063 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
GAA P10253 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27837215 0.94 FKBP1A (0.43) FKBP1AALDH1A1MAPK1LMNAHTT
Hydrochloric Acid SCHEMBL17593281 0.78 LMNA (0.37) ALDH1A1MAPK1LMNAHTTKMT2A
SCHEMBL19331435 0.76 POLB (0.42) ALDH1A1LMNAHTTKMT2AKDM4E
SCHEMBL27214198 0.74 TDP1 (0.67) ALDH1A1LMNAHTTKMT2AHPGD
SCHEMBL2512424 0.72 FKBP1A (0.69) FKBP1AALDH1A1MAPK1LMNAHTT
SCHEMBL24369504 0.71 MAPK1 (0.40) FKBP1AALDH1A1MAPK1LMNAHTT
SCHEMBL29488875 0.71 MAPK1 (0.40) FKBP1AALDH1A1MAPK1LMNAHTT
SCHEMBL29488928 0.71 CTSK (0.48) FKBP1AALDH1A1MAPK1LMNAHTT
SCHEMBL29086365 0.71 CTSK (0.48) FKBP1AALDH1A1MAPK1LMNAHTT
SCHEMBL30988530 0.69 PIK3C3 (0.46) FKBP1AALDH1A1MAPK1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067670-B2 Sulfamato hydroxamic acid metalloprotease inhibitor WARNER LAMBERT COMPANY (US) 2006-06-27 US disclosed
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2005-03-03 US disclosed
US-6800646-B1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2004-10-05 US disclosed
US-6492367-B1 Sulfamato hydroxamic acid metalloprotease inhibitor G. D. SEARLE & COMPANY 2002-12-10 US disclosed
US-6448250-B1 INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 G. D. SEARLE & COMPANY 2002-09-10 US disclosed
EP-1157021-A1 SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 2001-11-28 EP disclosed
WO-2000046221-A1 SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor MMP14, MMP12, MMP17 FKBP1A 858/4885ALDH1A1 784/4885MAPK1 2500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.